Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 35

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Type 2 diabetes mellitus

Not recruiting

A study to evaluate the effects of obicetrapib and ezetimibe on cholesterol levels in adults with type 2 diabetes or metabolic syndrome

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:NewAmsterdam Pharma B.V.

Diabetic retinal oedema

Not recruiting

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Obesity

Not recruiting

Orlistat (EMP22) and Drug Combination (acarbose + orlistat) in Healthy Volunteers with Obesity

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:ACARBOSE
  • Sponsor:Empros Pharma AB

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Safety, Tolerability and Pharmacokinetics of MK-7480 and Diltiazem Hydrochloride in Healthy Adult Male Participants for Non‑alcoholic Steatohepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Diltiazem Hydrochloride
  • Sponsor:Merck Sharp & Dohme LLC

Diabetes mellitus

Not recruiting

Bioequivalence Study of Dapagliflozin 10 mg Tablets in Healthy Adult Volunteers with Diabetes

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dapagliflozin
  • Sponsor:Sun Pharmaceutical Industries Limited

Iron overload

Not recruiting

Safety and Tolerability of REGN7999 in Healthy Adult Participants

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:REGN7999
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus

Not recruiting

Single‑dose Bioavailability of Gliclazide Modified‑Release Tablets in Healthy Volunteers (Type 2 Diabetes)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Gliclazide
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Diabetes mellitus

Not recruiting

Bioequivalence Study of Linagliptin 5 mg Film‑Coated Tablets in Healthy Volunteers for Diabetes Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Linagliptin
  • Sponsor:Laboratorios Alter S.A.

A study to evaluate how the body processes AZ-3102 in healthy male subjects

Not recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:(2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL
  • Sponsor:Azafaros B.V.

Obesity+1

Not recruiting

Phase 1 randomized, placebo-controlled study of ROSE-010 and paracetamol on appetite in overweight and obese adults

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Paracetamol
  • Sponsor:Rose Pharma Inc.

Type 2 diabetes mellitus

Not recruiting

A study testing ALN-4324 for safety and effectiveness in overweight to obese patients with type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALN-4324
  • Sponsor:Alnylam Pharmaceuticals Inc.

Primary hyperoxaluria

Not recruiting

Study of nedosiran for patients with primary hyperoxaluria type 1 and severe kidney impairment with or without dialysis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nedosiran
  • Sponsor:Dicerna Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.